Advertisement
Person › Details
Jörg Kreuzer (Boehringer Ingelheim (Group))
Kreuzer, Jörg (Boehringer Ingelheim 201604 VP Medicine, Therapeutic Area Cardiovascular)
Organisation | Boehringer Ingelheim (Group) | |
Product | cardiovascular drug | |
Product 2 | drug development | |
Record changed: 2018-02-20 |
Advertisement
More documents for Jörg Kreuzer
- [1] Boehringer Ingelheim. (11/15/17). "Press Release: Key Sub-analyses of RE-DUAL PCI Showed Large Reductions in the Incidence of Bleeding Complications if Pradaxa (dabigatran etexilate) Dual Therapy Was Used Instead of Warfarin Triple Therapy". Ingelheim....
- [2] Boehringer Ingelheim. (11/10/17). "Press Release: Boehringer Ingelheim Presents New Data for Pradaxa and Its Specific Reversal Agent Praxbind at AHA Scientific Sessions 2017". Ingelheim....
- [3] Boehringer Ingelheim. (6/21/17). "Press Release: New Data Reveal High Rates of Stroke History in Asymptomatic Atrial Fibrillation Patients". Ingelheim....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top